Entry Point Capital, LLC Rocket Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 24,903 shares of RCKT stock, worth $260,734. This represents 0.14% of its overall portfolio holdings.
Number of Shares
24,903Holding current value
$260,734% of portfolio
0.14%Shares
1 transactions
Others Institutions Holding RCKT
# of Institutions
243Shares Held
106MCall Options Held
268KPut Options Held
119K-
Rtw Investments, LP New York, NY17.7MShares$185 Million3.63% of portfolio
-
Wellington Management Group LLP Boston, MA14MShares$147 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.58MShares$68.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$64.8 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$54.4 Million1.26% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $792M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...